Glaukos director Klimans sells $288k in stock

Gilbert H. Kliman, a director at Glaukos Corp (NYSE:GKOS), recently executed a series of stock transactions, as disclosed in a filing with the Securities and Exchange Commission. The transactions come as the company’s stock trades near its 52-week high of $147.65, having delivered an impressive 74.78% return year-to-date according to InvestingPro data. On December 11, Kliman sold 2,000 shares of Glaukos’ common stock at an average price of $144.01 per share, totaling approximately $288,020. This sale was part of multiple trades executed at prices ranging from $144.00 to $144.05.

In addition to the sale, Kliman exercised stock options to acquire 2,000 shares at a price of $32.00 per share, which he then sold. Following these transactions, Kliman holds 32,336 shares of Glaukos common stock directly, including 2,611 restricted stock units that have yet to vest.

In other recent news, Glaukos Corporation has been the focus of several analyst upgrades and adjustments. Citi upgraded Glaukos stock to Buy from Neutral, citing a positive outlook on the company’s iDose product, which has seen its revenue double in the third quarter of 2024 to approximately $8 million. UBS also rated Glaukos stock as Buy, driven by the anticipated success of the iDose product and continued stent franchise growth. On the other hand, Stifel increased its price target for Glaukos shares to $153.00, maintaining a Buy rating, driven by optimism for iDose sales.

In addition to analyst upgrades, Glaukos has also secured approximately $53.2 million from unwinding a portion of its capped call transactions. This significant financial move is part of the company’s financial strategies surrounding its convertible senior notes. Furthermore, Glaukos has entered into agreements to partially unwind specific capped call transactions related to its convertible senior notes, a strategic move in managing its financial instruments.

These recent developments reflect the company’s ongoing efforts to enhance its financial position and market value. As analysts continue to monitor the company’s performance and potential, investors will likely pay close attention to the company’s future moves.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Related Posts

Carecloud director Cameron Munter sells $122,999 in stock

Cameron Munter, a director at CareCloud, Inc. (NASDAQ:CCLD), recently sold 30,000 shares of the company’s common stock. The transaction, which took place on December 11, 2024, was completed at a…

Read more

China’s GDP growth expected around 5% this year, senior official says

The world’s second-largest economy is expected to contribute close to 30% of global growth, Han Wenxiu told an economic conference. China’s foreign exchange reserves likely remained above $3.2 trillion this…

Read more

MicroStrategy secures Nasdaq-100 inclusion after bitcoin-fueled stock surge

The change comes into effect before the market opens on Dec. 23, Nasdaq said. Inclusion in the index typically boosts the stock’s price, as exchange-traded funds looking to replicate the…

Read more

Summit Midstream’s CEO sells $109,260 in stock

HOUSTON—Deneke J. Heath, Chairman, President, and CEO of Summit Midstream Corp (NASDAQ:NYSE:SMC), recently sold shares of the company in a series of transactions. The sales, conducted under a pre-arranged trading…

Read more

Ars Pharmaceuticals’ chief business officer sells $1.77m in stock

SAN DIEGO—Justin Chakma, the Chief Business Officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a pharmaceutical company with a market capitalization of $1.23 billion, recently executed a series of stock transactions, according…

Read more

Ukrainian drones hit fuel storage area in central Russia, attack other areas

Klychkov, writing on the Telegram messaging app, said a “mass attack” on an infrastructure site caused fuel to catch fire. Fragments from downed drones smashed windows in homes, he said….

Read more

Leave a Reply